147 related articles for article (PubMed ID: 32678075)
21. mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.
Finetti F; Terzuoli E; Giachetti A; Santi R; Villari D; Hanaka H; Radmark O; Ziche M; Donnini S
Endocr Relat Cancer; 2015 Aug; 22(4):665-78. PubMed ID: 26113609
[TBL] [Abstract][Full Text] [Related]
22. Ovarian cancer and normal fallopian tube high WFDC2 expression does not correlate with HE4 serum level.
Gąsiorowska E; Walkowiak GP; Warchoł W; Lemańska A; Jankowska A; Nowak-Markwitz E
Ginekol Pol; 2015 May; 86(5):335-9. PubMed ID: 26117969
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis based gene expression profiling reveals functional genes in ovarian cancer.
Zhao L; Li Y; Zhang Z; Zou J; Li J; Wei R; Guo Q; Zhu X; Chu C; Fu X; Yue J; Li X
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33135729
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling.
Tang Y; Pan J; Huang S; Peng X; Zou X; Luo Y; Ren D; Zhang X; Li R; He P; Wa Q
J Exp Clin Cancer Res; 2018 Jul; 37(1):160. PubMed ID: 30021600
[TBL] [Abstract][Full Text] [Related]
25. GABARAPL1 suppresses metastasis by counteracting PI3K/Akt pathway in prostate cancer.
Su W; Li S; Chen X; Yin L; Ma P; Ma Y; Su B
Oncotarget; 2017 Jan; 8(3):4449-4459. PubMed ID: 27966458
[TBL] [Abstract][Full Text] [Related]
26. FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR.
Li L; Zhang S; Li H; Chou H
BMC Cancer; 2019 Oct; 19(1):963. PubMed ID: 31619201
[TBL] [Abstract][Full Text] [Related]
27. [Expression and significance of WFDC2 in ovarian cancer based on multiple gene databases].
Lu J; Yang Y; Yan K; Deng Z; Zhang H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Jun; 34(6):528-534. PubMed ID: 30236206
[TBL] [Abstract][Full Text] [Related]
28. PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer.
Barber AG; Castillo-Martin M; Bonal DM; Jia AJ; Rybicki BA; Christiano AM; Cordon-Cardo C
Cancer Med; 2015 Aug; 4(8):1258-71. PubMed ID: 26033689
[TBL] [Abstract][Full Text] [Related]
29. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
[TBL] [Abstract][Full Text] [Related]
30. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway.
Zhou PJ; Xue W; Peng J; Wang Y; Wei L; Yang Z; Zhu HH; Fang YX; Gao WQ
J Exp Clin Cancer Res; 2017 Oct; 36(1):139. PubMed ID: 29017577
[TBL] [Abstract][Full Text] [Related]
31. ZNF703 promotes tumor progression in ovarian cancer by interacting with HE4 and epigenetically regulating PEA15.
Wang S; Wang C; Hu Y; Li X; Jin S; Liu O; Gou R; Zhuang Y; Guo Q; Nie X; Zhu L; Liu J; Lin B
J Exp Clin Cancer Res; 2020 Nov; 39(1):264. PubMed ID: 33246486
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor signaling promotes metastatic prostate cancer through microRNA-96-mediated downregulation of the tumor suppressor ETV6.
Tsai YC; Chen WY; Siu MK; Tsai HY; Yin JJ; Huang J; Liu YN
Cancer Lett; 2017 Jan; 384():1-8. PubMed ID: 27746161
[TBL] [Abstract][Full Text] [Related]
33. Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer.
Tsai YC; Zeng T; Abou-Kheir W; Yeh HL; Yin JJ; Lee YC; Chen WY; Liu YN
Mol Cancer; 2018 Feb; 17(1):42. PubMed ID: 29455655
[TBL] [Abstract][Full Text] [Related]
34. Targeting the SPOCK1-snail/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis.
Chien MH; Lin YW; Wen YC; Yang YC; Hsiao M; Chang JL; Huang HC; Lee WJ
J Exp Clin Cancer Res; 2019 Jun; 38(1):246. PubMed ID: 31182131
[TBL] [Abstract][Full Text] [Related]
35. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression.
Henderson V; Smith B; Burton LJ; Randle D; Morris M; Odero-Marah VA
Cell Adh Migr; 2015; 9(4):255-64. PubMed ID: 26207671
[TBL] [Abstract][Full Text] [Related]
36. PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway.
Shen H; He M; Lin R; Zhan M; Xu S; Huang X; Xu C; Chen W; Yao Y; Mohan M; Wang J
J Exp Clin Cancer Res; 2019 Jun; 38(1):247. PubMed ID: 31182136
[TBL] [Abstract][Full Text] [Related]
37. Novel tumor suppressor microRNA at frequently deleted chromosomal region 8p21 regulates epidermal growth factor receptor in prostate cancer.
Bucay N; Sekhon K; Majid S; Yamamura S; Shahryari V; Tabatabai ZL; Greene K; Tanaka Y; Dahiya R; Deng G; Saini S
Oncotarget; 2016 Oct; 7(43):70388-70403. PubMed ID: 27611943
[TBL] [Abstract][Full Text] [Related]
38. CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-α/EGFR pathway in hypoxic androgen-independent prostate cancer cells.
Tang J; Xiao L; Cui R; Li D; Zheng X; Zhu L; Sun H; Pan Y; Du Y; Yu X
Oncol Rep; 2016 Feb; 35(2):1153-62. PubMed ID: 26718770
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer.
Liao Y; Guo Z; Xia X; Liu Y; Huang C; Jiang L; Wang X; Liu J; Huang H
J Exp Clin Cancer Res; 2019 Apr; 38(1):157. PubMed ID: 30975171
[TBL] [Abstract][Full Text] [Related]
40. Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells.
Stewart JR; O'Brian CA
Mol Cancer Ther; 2005 May; 4(5):726-32. PubMed ID: 15897236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
